Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
The aim is to support Pharmacovigilance programme across the countries in the region
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
Acute therapies continue to report strong growth compared to chronic ones.
Support from DFC will help produce one billion vaccine doses by the end of 2022
Subscribe To Our Newsletter & Stay Updated
